Home
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
Company Overview
Corporate Strategy
Management Team
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
中国 — 简体中文
Global — English
Home
Technology Platforms
BACK
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
BACK
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
BACK
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
BACK
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
BACK
About Us
Company Overview
Corporate Strategy
Management Team
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
BACK
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
Newsroom
Strive to Deliver Breakthroughs
Press Release
particular year
Please select
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
05
Please select
01
02
03
04
05
06
07
08
09
10
11
12
2026-05-18
Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
2026-05-08
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
2026-05-08
Harbour BioMed Invests in Windward Bio鈥檚 $165M Financing to Advance Pipeline of Long-Acting Immunology Therapies
2024-05-23
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
2023-05-26
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023
2022-05-25
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody
2022-05-10
Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting
2022-05-06
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board
2021-05-11
Harbour BioMed Announces Dosing of First Patient in Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody
2020-05-04
Utrecht University, Erasmus Medical Center and Harbour BioMed Researchers Report Discovery of Antibody that Blocks Novel Coronavirus SARS-CoV-2 Infection in Cells
1
2
Jump